The pharmaceutical industry is facing an ongoing issue with genotoxic impurities (GTIs). Over the past year, we have witnessed genotoxic impurities affect several drugs, including those used to treat elevated blood pressure, heartburn and acid reflux. Angiotensin II...
You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to...
Read time: 3 Minutes A powerful combination: The Zeno trap and electron activated dissociation (EAD) fragmentation Sensitivity is a fundamental performance characteristic of a mass spectrometer. Increasingly higher sensitivities are in constant demand in order to...
Read time: 5 minutes In our previous blogs we discussed the need for a more comprehensive approach for monitoring contaminants in finished drug products.1,2 Here we cover a generalized approach for the targeted, quantitative LC-MS/MS analysis of several commonly...
The Echo® MS system is an exciting new platform that dramatically speeds sample analysis for quantitative MS studies. Because of its unique and innovative technology, the system can analyze samples faster than ever before - but without the need for liquid...
Imagine the productivity gains your lab could achieve with a technology that not only analyzes samples up to 50x faster than conventional quantitative LC-MS, but also eliminates tedious sample preparation, time-consuming LC method development and chromatographic run...
How fast is fast? Cheetahs. Usain Bolt. Tachyons. The Echo® MS system. What do these things have in common? They’re all fast. REALLY fast. In fact, they’re the fastest in their categories: the fastest land mammal, the fastest human sprinter, the fastest subatomic...
In my previous blog, I spoke about the FDA recall of angiotensin II receptor blockers like losartan. This recall was due to the presence of genotoxic nitrosamines. Is a proactive approach the way to mitigate risk? Recently, the FDA has re-issued the 2018 guidance to...
What if we could understand and then treat diseases on an individualized level, in a way that was tuned to a person’s individual biology? Not in a futuristic, ‘wave a high-tech scanner across a person’s body’ way, but in a legitimate ’I can run a lab test and know...
White House, EU, UK, and Australia Make Major Investments What if we could deliver the right treatment at the right time, to the right person to better, more effectively treat complex diseases? This is the promise of precision medicine, to be able to approach...